Search
Olmesartan
go.drugbank.com/drugs/DB00275ApprovedInvestigationalARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling. … [A175330] It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.[A175345, L12882]
Mixtures: OPENVAS CO, ALMETEC-COCarbon monoxide
go.drugbank.com/drugs/DB11588ApprovedInvestigationalThe DLCO measures the ability of the lungs to transfer gas from inhaled air to the red blood cells in pulmonary capillaries. The DLCO test is both convenient and simple for the patient to undergo. … to have some normal biological/homeostatic functions [L2529].
Mixtures: Lung Diffusion Test Mix No Ne Co, Co-NE-O2-N2 MixtureSynonyms: COAlefacept
go.drugbank.com/drugs/DB00092ApprovedWithdrawnProduced by CHO cells, mW is 91.4 kD. … Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of
Calcitriol
go.drugbank.com/drugs/DB00136ApprovedInvestigationalNutraceuticalIn addition to promoting fatty acid synthesis and inhibiting lipolysis, calcitriol has been demonstrated to increase energy efficiency by suppressing UCP2 expression, which is modulated by signaling pathways … to [DB00146] in the liver and kidneys.
Products: RO-CAL 0.25mcgDoravirine
go.drugbank.com/drugs/DB12301ApprovedInvestigationalDoravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines. … [L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg).
Selexipag
go.drugbank.com/drugs/DB11362ApprovedInvestigationalSelexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary
Diroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigationalThis drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. … Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019[L9626] and by the EMA in November 2021.[L39225]
Raltegravir
go.drugbank.com/drugs/DB06817ApprovedInvestigationalRaltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. … Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Tegafur-uracil
go.drugbank.com/drugs/DB09327ApprovedIt was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.
Azelaic acid
go.drugbank.com/drugs/DB00548ApprovedInvestigationalAzelaic acid's antimicrobial action may be attributable to inhibition of microbial cellular protein synthesis. … It works in part by stopping the growth of skin bacteria that cause acne, and by keeping skin pores clear.